ERBB2 and neoplasm: Recently, trispecific antibodies against HER2, CD3, and CD28 (a marker of T cells) have been developed and shown to promote antitumor immunity against HER2-positive breast tumors through CD4+-mediated tumor inhibition, highlighting the role of this immune subtype in addition to CD8+ T cells [78].